One more error to avoid
One more error to avoid
Serious adverse events have occurred recently from dispensing errors involving Lamictal (lamotrigine) and Lamisil (terbinafine) tablets, according to MedWatch Report. The antiepileptic agent Lamictal has been dispensed when the antifungal Lamisil was prescribed, and vice versa.
Glaxo Wellcome, manufacturer of Lamictal, issued a letter to pharmacists dated June 6, 2000, reporting the errors and asking that pharmacists be alert for prescriptions of both drugs. Proper measures to avoid errors should be assessed and implemented as appropriate. Any dispensing errors should be reported to Glaxo Wellcome, (800) 334-4135, for Lamictal; Novartis Pharmaceuticals, (888) 669-6682, for Lamisil; the USP Medication Errors Reporting Program, (800) 233-7767; or the FDA MedWatch Program, (800) FDA-1088.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.